MÉTODOS PARA TRATAR TRANSTORNOS OBSESSIVO-COMPULSIVOS RELACIONADOS, TRANSTORNOS DE TIQUE E TRANSTORNOS RELACIONADOS À EXCITOTOXICIDADE DO GLUTAMATO

Betahistine and histamine receptor modulators address the inadequacies of current treatments for OCD, tic disorders, and glutamate-related conditions by enhancing glutamate clearance and neurotransmitter modulation, effectively reducing symptoms and improving quality of life.

BR112025018034A2Pending Publication Date: 2026-11-10BIOHAVEN THERAPEUTICS LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
BR112025018034
Authority / Receiving Office
BR · BR
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-08-10
Filing Date
2024-02-28
Publication Date
2026-11-10

AI Technical Summary

Technical Problem

Current treatments for obsessive-compulsive disorder (OCD), tic disorders, autism spectrum disorder (ASD), and disorders related to glutamate excitotoxicity, such as amyotrophic lateral sclerosis (ALS), are inadequate, with many patients not responding to existing therapies and experiencing debilitating symptoms due to limited efficacy and significant side effects.

Method used

Administering therapeutically effective amounts of betahistine or its pharmaceutically acceptable salts, analogues, metabolites, prodrugs, derivatives, cocrystals, modifications, solvates, hydrates, isotopes, tautomers, esters, polymorphs, or stereoisomers, or a combination of H1R agonists and H3R antagonists, to modulate histamine and glutamate signaling, thereby reducing symptoms.

Benefits of technology

Enhances glutamate clearance, modulates neurotransmitter release, and improves synaptic homeostasis, leading to reduced symptoms in OCD, tic disorders, ASD, and glutamate-related disorders, with potential synergistic effects when combined with other medications or neuromodulation techniques.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The present invention provides for methods of treating obsessive-compulsive disorder (OCD) and OCD-related disorders (body dysmorphic disorder, hoarding disorder, trichotillomania (hair-pulling disorder), excoriation (skin-picking) disorder, substance / medication-induced obsessive-compulsive and related disorder, obsessive- compulsive and related disorder due to another medical condition, and other specified and unspecified obsessive-compulsive and related disorders), Tic disorders including Tourette syndrome, autism spectrum disorder (ASD) and glutamate excitotoxicity related disorders including amyotrophic lateral sclerosis (ALS), Parkinson's disease, traumatic brain injury, multiple sclerosis, Huntington's disease, and schizophrenia, comprising the step of administering an effective amount of a histamine type 1 receptor agonist and / or histamine type 3 receptor antagonist, such as betahistine or its pharmaceutically acceptable salts, analogs, metabolites, prodrugs, derivatives, metabolites, co-crystals, modifications, solvates, hydrates, isotopes, tautomers, esters, polymorphs or stereoisomers.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] The present invention relates to the use of pharmaceutically acceptable histamine H1 receptor agonists and / or histamine H3 receptor antagonists, such as betahistine or its salts, analogues, metabolites, prodrugs, derivatives, metabolites, cocrystals, modifications, solvates, hydrates, isotopes, tautomers, esters, polymorphs or stereoisomers, for the treatment of related obsessive-compulsive disorders (OCDs), including obsessive-compulsive disorder (OCD), tic disorders, including Tourette syndrome, autism spectrum disorder (ASD), and disorders related to glutamate excitotoxicity, including amyotrophic lateral sclerosis (ALS). BACKGROUND OF THE INVENTION

[0002] Obsessive-compulsive disorder (OCD) is a chronic and highly debilitating neuropsychiatric disorder characterized by compulsions and / or obsessions. An obsession is a thought, feeling, or image that is intrusive, irrational, or clearly excessive, distressing, difficult to control, and stereotyped or repetitive in nature. Compulsions (also sometimes called rituals) are repetitive behaviors that are irrational or clearly excessive, difficult to control, and often stereotyped in nature; an individual typically feels compelled to perform compulsions in response to their obsessions.

[0003] The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V) classifies OCD under obsessive-compulsive and related disorders (OCDs), along with hoarding disorder, body dysmorphic disorder, trichotillomania (hair-pulling disorder), and excoriation (skin-picking disorder). OCD is often portrayed as an amusing personality quirk in popular culture, but in fact, it is a source of great suffering and profoundly affects quality of life, reducing sufferers' ability to maintain relationships and weakening other aspects of social and occupational functioning. Petition 870260106243, dated 10 / 15 / 2026, page 6 / 106 2 / 35

[0004] OCD has a lifetime prevalence of 2-3%. Women are 1.6 times more likely than men to be diagnosed with OCD at some point in their lives, and 92.3% of individuals seeking treatment for OCD have comorbidities, which also vary depending on sex. In women, eating disorders, anxiety, and depression are the most common comorbidities, while in men, attention deficit / hyperactivity disorder, autism, and psychotic and developmental disorders are more common. Any comorbidity in OCD is associated with greater symptoms of anxiety and depression, including suicidal behaviors.

[0005] The pathophysiology of OCD is complex and has been associated with genetic, infectious / autoimmune, endocrine, postpartum, and post-ischemic factors. Abnormalities of the cortico-striato-thalamo-cortical (CST) circuit, which controls habit formation, reward, and movement execution, have been repeatedly demonstrated. The neurotransmitter glutamate is prominent in this circuit; converging evidence suggests that glutamate abnormalities may contribute to the pathophysiology of OCD, and glutamate modulators are under investigation as potential therapeutics.

[0006] The general principles of OCD management include specialized cognitive behavioral therapy (CBT), which has consistently been shown to improve OCD symptomatology, and selective serotonin reuptake inhibitors (SSRIs), which are the first-line pharmacotherapy due to their relative safety and efficacy. SSRIs are typically used at much higher doses than in major depression, which is associated with increased adverse effects and therefore a higher treatment dropout rate.

[0007] Despite these different treatment methods, 40-60% of patients with OCD do not respond adequately to available evidence-based treatments. Approximately 30% do not respond at all; others improve and are categorized in studies as responders to treatment, but continue to experience debilitating symptoms. Available medications are limited by side effects (especially when second-line agents, such as clomipramine, or drug combinations, such as the addition of a neuroleptic, are used after non-response to SSRIs). Specialized CBT is limited by a markedly inadequate availability of qualified professionals. Petition 870260106243, dated 10 / 15 / 2026, page 7 / 106 3 / 35 focused on these effective therapeutic techniques.

[0008] Due to the nature of its symptoms and the lack of effective treatment, OCD continues to be a significant social burden, and the need for improved treatment methods remains. The decrease in the quality of life of patients with OCD, compared to their healthy counterparts, is comparable to that of patients with schizophrenia. In the World Health Organization's 2004 Global Burden of Disease Update, OCD was the cause of more disability-adjusted life years (number of years lost due to disability) than Multiple Sclerosis and Parkinson's Disease combined.

[0009] Histamine is an important neurotransmitter and modulator of the central nervous system, although its roles have been investigated less intensively than those of other modulating neurotransmitters, such as serotonin. Histaminergic neurons are found exclusively in the posterior tuberomammillary nucleus of the hypothalamus, but project widely throughout the brain. The enzyme histidine decarboxylase (Hdc) is essential for producing histamine, which is synthesized from the amino acid L-histidine by decarboxylation. A nonsense mutation in the Hdc gene has been detected as a rare but highly penetrant cause of Tourette Syndrome (TS), with comorbid OCD in about half of the identified cases. Further genetic studies and preclinical work corroborate a causal role of histamine signaling dysfunction in these conditions. Pharmacological testing of histaminergic agents in OCD and TS has been limited.

[0010] There are four histamine receptors. Histamine receptor 1 (H1R) is coupled via the Gaq / 11 protein to phospholipase C signaling. H1R is present in cerebral blood vessels, as well as in neurons and glial cells in many brain regions. Activation of H1R in astrocytes helps maintain synaptic homeostasis, including extracellular Ca2+ uptake, which increases intracellular Ca2+ and therefore affects Ca2+-dependent signaling.

[0011] The H3 receptor (H3R) is believed to be expressed exclusively in neurons in the central nervous system. It exists primarily presynaptically, in the axonal terminals of neurons. It is coupled to signaling via the protein Petition 870260106243, dated 10 / 15 / 2026, page 8 / 106 4 / 35 Gai, in this way, reduces signaling through cyclic AMP (cAMP). Activation of the presynaptic H3R reduces the release of neurotransmitters, including histamine itself (thus constituting a negative feedback mechanism), as well as glutamate, dopamine, and other transmitters. More recently, it has been recognized that a large part of the H3R in the striatum, the large input nucleus of the CETC circuit implicated in OCD, is postsynaptic; it interacts with dopamine signaling in complex ways. The H3R is most strongly expressed in the hypothalamus, basal ganglia, hippocampus, and cerebral cortex; this pattern overlaps with structures implicated in the pathophysiology of OCD.

[0012] Glutamate is the most abundant excitatory neurotransmitter in the Central Nervous System (CNS). Virtually all circuits and networks in the CNS use glutamate, including those involved in OCD, such as the CETC. Glutamate is released from vesicles into the synaptic cleft, where it can bind to presynaptic or postsynaptic receptors. Glutamate concentration is tightly regulated, as excess glutamate can cause excitotoxicity, which leads to neuronal death. A key mechanism of glutamate homeostasis is uptake by specific transporters in glial cells, primarily GLT-1 and GLT-2, which mediate the rapid uptake of extracellular glutamate after synaptic release.

[0013] Glutamate excitotoxicity is observed in numerous diseases, including ALS, Parkinson's disease, traumatic brain injury, stroke, Huntington's disease, and schizophrenia. Impaired glutamate uptake by transporters such as GLT-1 and GLT-2 and the consequent disruption of glutamate homeostasis may contribute to this excitotoxicity. Prolonged exposure to excessive extracellular glutamate increases neuronal susceptibility to excitotoxic cell death.

[0014] Furthermore, glutamate plays a crucial role in Autism Spectrum Disorder (ASD). Studies have shown that the balance of glutamate signaling is disrupted in individuals with ASD, leading to alterations in synaptic function and connectivity. Abnormalities in glutamate receptors and transporters, as well as imbalances in glutamate levels, have been observed in several brain regions implicated in ASD, such as the prefrontal cortex and the limbic system. Dysregulation of glutamate transmission can affect several Petition 870260106243, dated 10 / 15 / 2026, p. 9 / 106 5 / 35 aspects of neurodevelopment, including synaptic plasticity, neuronal migration, and circuit formation, all of which are crucial for normal brain function. Therefore, increasing glutamate clearance is a viable approach for several conditions.

[0015] Betahistine is used in the therapeutic management of vertigo and Meniere's disease. It works by increasing blood flow within the stapedial artery in the inner ear, consequently reducing vestibular pressure and mitigating symptoms such as vertigo and tinnitus. However, the clinical use of betahistine is not without limitations. Its relatively short half-life necessitates multiple daily doses, and it can cause gastrointestinal side effects in certain patients. SUMMARY OF THE INVENTION

[0016] Several aspects of the present invention address the challenges above.

[0017] In one embodiment, a method of treating a related obsessive-compulsive disorder (OCD) is provided, comprising administering to an individual in need thereof a therapeutically effective amount of betahistine or a pharmaceutically acceptable prodrug, derivative, metabolite, cocrystal, modification, salt, free acid or base, solvate, hydrate, isotope, tautomer, ester, polymorph or stereoisomer thereof.

[0018] In another embodiment, a method of treating an obsessive-compulsive disorder related to OCD in a human being is provided, comprising administering orally, to a human being in need of such treatment, an effective amount of an H1R agonist and / or an H3R antagonist or a pharmaceutically acceptable salt thereof or a pharmaceutical composition thereof.

[0019] In another embodiment, a method is provided for treating disorders related to glutamate excitotoxicity in a human being, comprising administering orally, to a human being in need of such treatment, an effective amount of an H1R agonist and / or an H3R antagonist or a pharmaceutically acceptable salt, metabolite or prodrug thereof.

[0020] In another modality, a treatment method is provided for Petition 870260106243, dated 10 / 15 / 2026, page 10 / 106 6 / 35 disorders related to glutamate excitotoxicity, comprising administering to an individual in need thereof a therapeutically effective amount of betahistine or a pharmaceutically acceptable prodrug, derivative, metabolite, cocrystal, modification, salt, free acid or base, solvate, hydrate, isotope, tautomer, ester, polymorph or stereoisomer thereof.

[0021] In another embodiment, a method of treating tic disorders is provided, comprising administering to an individual in need thereof a therapeutically effective amount of betahistine or of a pharmaceutically acceptable prodrug, derivative, metabolite, cocrystal, modification, salt, free acid or base, solvate, hydrate, isotope, tautomer, ester, polymorph or stereoisomer thereof.

[0022] In another embodiment, a method of treating autism spectrum disorder (ASD) in a human being is provided, comprising administering orally, to a human being in need of such treatment, an effective amount of betahistine or a pharmaceutically acceptable prodrug, derivative, metabolite, cocrystal, modification, salt, free acid or base, solvate, hydrate, isotope, tautomer, ester, polymorph or stereoisomer thereof. LIST OF FIGURES

[0023] FIG. 1A graphically represents the variation in ambulatory activity count through amphetamine use in Example 1.

[0024] FIG. 1B graphically represents the variation in ambulatory activity count through amphetamine in two 30-minute intervals from Example 1.

[0025] FIG. 1C represents the increase in stereotypy after stimulation with amphetamine and its blockade by pretreatment with betahistine from Example 1.

[0026] FIG. 1D represents the stereotypy after amphetamine stimulation from Example 1.

[0027] FIG. 2A represents locomotor activation after amphetamine in the HomeCageScan environment of Example 2.

[0028] FIG. 2B represents the increase in locomotion in the first 30 minutes after amphetamine stimulation from Example 2.

[0029] FIG. 2C represents the amphetamine stimulus that led to the increase Petition 870260106243, dated 10 / 15 / 2026, page 11 / 106 7 / 35 of the self-cleaning from Example 2.

[0030] FIG. 2D represents self-cleaning at two 30-minute intervals after amphetamine stimulation in Example 2.

[0031] FIG. 3 represents medical school grades before and after treatment with betahistine. DETAILED DESCRIPTION OF THE INVENTION

[0032] The following detailed description is provided to assist those skilled in the art in practicing the present invention. Exemplary embodiments will be described in detail in the following sections. However, these embodiments are only exemplary, and the present disclosure is not limited to them, but is rather defined by the scope of the appended claims. Persons with ordinary knowledge of the art may make modifications and variations on the embodiments described herein in this patent application without departing from the spirit or scope of this disclosure.

[0033] Unless otherwise defined, all technical and scientific terms used herein in this patent application have the same meaning as commonly understood by someone with ordinary knowledge of the art to which this disclosure belongs. The terminology used in the description is for the purpose of describing particular embodiments only and is not intended to be limiting. It will further be understood that terms, such as those defined in commonly used dictionaries, are to be interpreted as having a meaning consistent with their meaning in the context of the relevant art and the present disclosure, and will not be interpreted in an idealized or overly formal sense unless expressly defined as such herein in this patent application.

[0034] As used in this application, except where expressly provided otherwise herein, in this patent application, each of the following terms shall have the meaning set forth below. Additional definitions are set forth throughout the application. In cases where a term is not specifically defined herein, in this patent application, that term is given a meaning recognized in the art by those of ordinary knowledge who apply that term in context to its use in the description of the present invention.

[0035] The articles "um" and "uma" refer to one or more of "um" (i.e., to no Petition 870260106243, dated 10 / 15 / 2026, p. 12 / 106 8 / 35 minimum one) of the grammatical object of the article, unless the context clearly indicates otherwise. For example, an element means one element or more than one element.

[0036] Therefore, embodiments are merely described below, referring to structures and schemes, to explain aspects of the present description. As used herein, in this patent application, the term and / or includes any and all combinations of one or more of the associated listed items. The term or means and / or. Expressions such as at least one of, when preceding a list of elements, modify the entire list of elements and do not modify the individual elements of the list.

[0037] It is understood that the terms comprise and / or including, or include and / or including, when used in this specification, specify the presence of declared substituents, groups, features, regions, integers, steps, operations, elements and / or components, but do not exclude the presence or addition of one or more other substituents, groups, features, regions, integers, steps, operations, elements, components and / or groups thereof.

[0038] The present methods, compounds and systems are not limited to specific methods, compounds, components or compositions described or exemplified herein in this patent application. It should also be understood that the terminology used herein in this patent application is for descriptive purposes and is not intended to be limiting.

[0039] Betahistine is a histamine analogue discovered in the 1970s. It is widely used as an anti-vertigo medication, although controlled studies supporting this use are equivocal. Betahistine is currently approved for the treatment of Meniere's disease in more than 80 countries. It was approved by the United States Food and Drug Administration (US FDA), but due to concerns about its effectiveness in treating Meniere's disease, the approval was revoked. Since then, the FDA has concluded that while there is no evidence that betahistine is unsafe, there is insufficient evidence to conclude that it has a therapeutic effect against Meniere's disease. Therefore, it remained unavailable in the United States for decades.

[0040] Betahistine is a weak agonist of the histamine H1R and an antagonist Petition 870260106243, dated 10 / 15 / 2026, page 13 / 106 9 / 35 strong of H3R. Therefore, it may act on processes relevant to OCD, OCD-related disorders, and ST in multiple ways: through disinhibition of histamine release (and therefore mitigation of the histamine reduction observed in individuals with a mutation in the Hdc gene); through direct action on neurons in the CETC circuit, including in the striatum; through modulation of glial cell activity and function; and through modulation of cerebral blood flow. Betahistine's actions on cochlear blood vessels have been proposed to mediate its effects in Meniere's disease – although, again, the evidence of benefit in controlled trials is equivocal, and it is not approved for this or any other indication by the US FDA.

[0041] An important consequence of H1 receptor activation is neuroprotection, by preventing glutamate excitotoxicity through increased glutamate clearance. Glutamate is removed from the synaptic cleft by astrocytic glutamate transporters, especially GLT-1 (also known as excitatory amino acid transporter 2 or EAAT2). Once transported to astrocytes, glutamate is converted to glutamine by the enzyme glutamine synthetase (GS). GLT-1 is responsible for the vast majority of glutamate reuptake (up to 90% in mechanistic studies in mice). H1R activation positively regulates both GLT-1 and GS; this will reinforce the mechanisms of glutamate uptake and metabolism, decreasing the amount of glutamate in the synaptic cleft.Without limiting the invention, it has been suggested that enhanced glutamate reuptake may be an additional mechanism by which betahistine and similar drugs may reduce symptoms in patients with OCD.

[0042] Of note, other drugs that enhance glutamate reuptake, such as riluzole, are under investigation in the treatment of OCD. Riluzole is currently the only FDA-approved drug for the treatment of amyotrophic lateral sclerosis. H1 agonism may produce enhanced effects on glutamate reuptake compared to riluzole because it upregulates both GLT-1 (as riluzole does) and GS (which riluzole does not), producing a synergistic effect.

[0043] H3R antagonists have recently been viewed as a promising drug target for cognitive disorders due to their various pro-cognitive effects, including increased alertness, attention, and learning and memory. It was Petition 870260106243, dated 10 / 15 / 2026, page 14 / 106 10 / 35 demonstrated that they increase wakefulness and slow-wave sleep (SWS), while reducing rapid eye movement (REM) sleep. H3R antagonists, in addition to increasing histamine release, also increase the release of norepinephrine, dopamine, and acetylcholine.

[0044] Betahistine, or its salts, analogues, metabolites, prodrugs, derivatives, metabolites, cocrystals, modifications, solvates, hydrates, isotopes, tautomers, esters, polymorphs or stereoisomers that are pharmaceutically acceptable, may be administered according to various dosage regimens. For example, betahistine, or its salts, metabolites and pharmaceutically acceptable prodrugs, may be administered once daily, twice daily, three times daily, or more than three times daily. In some cases, betahistine, or its pharmaceutically acceptable salts, metabolites, and prodrugs, may be administered less than once a day, for example, once every two days, once every three days, once every five days, once every seven days, once every ten days, once every fourteen days, once every twenty-eight days, or once a month.

[0045] Betahistine, or its salts, analogues, metabolites, prodrugs, derivatives, metabolites, cocrystals, modifications, solvates, hydrates, isotopes, tautomers, esters, polymorphs or stereoisomers that are pharmaceutically acceptable, may be administered in such a way that the total weekly dose is at least 50 mg, at least 100 mg, at least 250 mg, at least 500 mg, at least 750 mg, at least 1,000 mg, at least 1,250 mg, at least 1,500 mg, at least 1,750 mg or at least 2,000 mg. In some cases, the total weekly dose may be 5 to 5,000 mg, 10 to 5,000 mg, 10 to 2,500 mg, 50 to 2,500 mg, 100 to 2,500 mg, 100 to 2,000 mg, 250 to 2,000 mg, or 500 to 2,000 mg.

[0046] Dosage regimens include adult dosages of 24 to 48 mg administered in multiple doses throughout the day, such as, but not limited to, 16 mg of betahistine every 8 hours (e.g., per tablet), preferably taken after meals during the first two weeks. After that, an acceptable maintenance dose is 8 mg of betahistine every 8 hours. Other dosage regimens within the scope of the present invention include a protocol of 32 mg of betahistine (e.g., orally) every 8 hours as monotherapy. Another dosage regimen within the scope of the present invention is 32 mg of betahistine (e.g., orally) every 8 hours, in conjunction with Petition 870260106243, dated 10 / 15 / 2026, page 15 / 106 11 / 35 combination with 50 mg of riluzole (e.g., orally) every 12 hours.

[0047] For the treatment of OCD according to the invention, betahistine, or its salts, analogues, metabolites, prodrugs, derivatives, metabolites, cocrystals, modifications, solvates, hydrates, isotopes, tautomers, esters, polymorphs or stereoisomers that are pharmaceutically acceptable, may be administered in combination with one or more other medications, including, but not limited to, one or more serotonin reuptake inhibitors (SSRIs), including, but not limited to, fluoxetine, fluvoxamine, paroxetine, sertraline, escitalopram, citalopram, clomipramine, venlafaxine, mirtazapine, among others, one or more monoamine oxidase inhibitors (MAOIs), including, but not limited to, d-amphetamine, glutamate modulating agents (such as memantine, N-acetylcysteine ​​and ketamine, among others). others), pregabalin, topiramate, lamotrigine, clonazepam and other benzodiazepines, lithium, buspirone, psilocybin or carbamazepine.

[0048] Riluzole has been studied as an adjunctive treatment for refractory OCD. The mechanism by which the therapeutic effects are thought to occur is the upregulation of GLT-1, which is shared by H1 agonism in rat models, which also increases the upregulation of GS. Without being limited by any specific mechanism of action, betahistine in combination with riluzole could cause an amplified clearance of glutamate, which, in turn, would decrease the symptoms of OCD.

[0049] The combination of MAOIs and betahistine in rat models showed amplified H1 agonism with minimal doses of betahistine, demonstrated by increased cochlear blood flow, which is a sign of H1 agonism. H1 agonism then leads to increased upregulation of GS and GLT-1, as mentioned earlier, and to a reduction in OCD symptoms and / or a reduction in glutamate excitotoxicity.

[0050] Betahistine, or its salts, analogues, metabolites, prodrugs, derivatives, metabolites, cocrystals, modifications, solvates, hydrates, isotopes, tautomers, esters, polymorphs or stereoisomers that are pharmaceutically acceptable, can also be used to treat OCD according to the invention in combination with neuromodulation techniques, such as tDCS, TMS, VNS, DBS, among others.

[0051] For the treatment of ALS according to the invention, betahistine, or Petition 870260106243, dated 10 / 15 / 2026, page 16 / 106 12 / 35 its salts, analogues, metabolites, prodrugs, derivatives, metabolites, cocrystals, modifications, solvates, hydrates, isotopes, tautomers, esters, polymorphs or stereoisomers that are pharmaceutically acceptable, may be administered in combination with one or more other medications, including, but not limited to, riluzole, baclofen, diazepam, gabapentin, trihexyphenidyl and amitriptyline.

[0052] Riluzole has been approved by the US FDA for the treatment of ALS; it is believed to mitigate excitotoxicity. The mechanism causing the therapeutic effects is thought to be its increased glutamate clearance, achieved through the upregulation of GLT-1. This is shared by betahistine and other H1R agonists, except that they also lead to the upregulation of GS, which is predicted to further increase glutamate clearance through bulk action.

[0053] For the treatment of Parkinson's disease according to the invention, betahistine, or its salts, analogues, metabolites, prodrugs, derivatives, metabolites, cocrystals, modifications, solvates, hydrates, isotopes, tautomers, esters, polymorphs or stereoisomers that are pharmaceutically acceptable, may be administered in combination with one or more other medications, including, but not limited to, levodopa, carbidopa, dopamine agonists such as cabergoline, among others, MAO-B inhibitors, COMT inhibitors, amantadine, anticholinergic drugs such as trihexyphenidyl, benztropine, orphenadrine, procyclidine and biperiden, among others.

[0054] For the treatment of tic disorders according to the invention, betahistine, or its salts, analogues, metabolites, prodrugs, derivatives, metabolites, cocrystals, modifications, solvates, hydrates, isotopes, tautomers, esters, polymorphs or stereoisomers that are pharmaceutically acceptable, may be administered in combination with one or more other medications, including, but not limited to, first-, second- or third-generation antipsychotics, tetrabenazine and topiramate.

[0055] For the treatment of autism spectrum disorder (ASD) according to the invention, an effective amount of a pharmaceutically acceptable H1R agonist and / or H3R antagonist, such as betahistine, or its salts, analogues, metabolites, prodrugs, derivatives, cocrystals, modifications, solvates, hydrates, isotopes, tautomers, esters, polymorphs or stereoisomers, may be Petition 870260106243, dated 10 / 15 / 2026, p. 17 / 106 13 / 35 is optionally administered in combination with one or more other medications.

[0056] Combinations for use in the methods of the invention include, but are not limited to, betahistine or its salts, analogues, metabolites, prodrugs, derivatives, metabolites, cocrystals, modifications, solvates, hydrates, isotopes, tautomers, esters, polymorphs or stereoisomers that are pharmaceutically acceptable, in combination with a. a monoamine oxidase inhibitor (MAOI), such as selegiline; b. a benzothiazole or derivative, such as riluzole, pramipexole, troriluzole or a combination thereof; c. a skeletal muscle relaxant, such as baclofen, dantrolene, or a combination thereof; d. a benzodiazepine, such as diazepam, clonazepam, or a combination thereof; e. an anticonvulsant, such as gabapentin, topiramate, lamotrigine, carbamazepine, BHV-7000, BHV-7010, BHV-80000, any Kv7.2 / 7.3 activator, any Kv7.4 activator, any Kv7 activator, or a combination thereof; f. an anticholinergic drug such as trihexyphenidyl, benztropine, orphenadrine, procyclidine, biperiden, or a combination thereof; e.g. a tricyclic, tetracyclic or other antidepressant drug, such as amitriptyline and mirtazapine; h. a first-generation antipsychotic, a second-generation antipsychotic, a third-generation antipsychotic, such as risperidone, aripiprazole, or a combination thereof; I. tetrabenazine or topiramate. j. a glutamate-modulating agent, such as memantine, N-acetylcysteine, ketamine, D-cycloserine, or a combination thereof; k. a serotonin reuptake inhibitor (SSRI), such as clomipramine, fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, escitalopram, or a combination thereof, l. a psychostimulant, atomoxetine, or alpha-2 receptor blocker, Petition 870260106243, dated 10 / 15 / 2026, p. 18 / 106 14 / 35 such as clonidine, guanfacine, methylphenidate or a combination thereof; m. a histamine analogue, a histamine derivative, L-Histidine, HTMT (histamine N-methyltransferase), or a histamine precursor or prodrug; n. an H1 agonist, such as methylhistaprodifene, dimethylhistaprodifene, 2-thiazolylethylamine, 2-pyridylethylamine, suprahistaprodifene. 2-(2-aminoethyl)pyridine (2-PyEA), 2-phenylhistamine, such as 2-[3-(trifluoromethyl)phenyl]histamine, 2-(3-chlorophenyl)histamine, N-methyl-2-[3-(trifluoromethyl)phenyl]histamine, histaprodifen (2-[2(3,3-diphenylpropyl)-1H-imidazol-4-yl]ethanamine), supra-histaprodifen (N-2-[(1H-imidazol-4-yl)ethyl]histaprodifen-(2-aminoethyl)imidazole (2-ImEA), or an H1 agonist synthesized from a new orientation or alteration in the imidazole ring, or combinations thereof; o. an H3 antagonist or inverse agonist, such as A-960656, ABT239, ABT-288, ABT-652, ABT-834, APD-916, AZD-5213, bavisanto (BEN2001, JNJ1074, JNJ31001074), betahistine (AM125, AM201), BP1.3656, CEP-32215, cipralisant, ciproxfan, clobenpropit, DL-76, DL-77, E-100, E-162, enerisant, GR175737, GSK- 1004723, GSK-189254, GSK207040, GSK-239512, GSK-334429, GSK-835726, GT-2016, HPP-404, irdabisanthus (CEP-26401), JNJ-17216498, JNJ39220675, JNJ5207852, LC-1405, LGD-3437, LML-134, MK-0249, MK-3134, MK7288, PF-03654746, pitolisant (BF2649), S013-1593, S-38093, samelisant (SUVN G3031), SAR-110894, SAR-152954, SCH-497079, SLS-010, ST-1283, thioperamide, ZPL-868087, or combinations thereof.

[0048] The invention also relates to betahistine prodrugs designed to overcome the limitations associated with the original drug, while maintaining or enhancing its therapeutic efficacy. The prodrugs, resulting from the conjugation of betahistine with various functional groups or molecular structures, are designed to modify the pharmacokinetic profile of betahistine, providing significant improvements in terms of stability, absorption and half-life.

[0049] One aspect of the invention relates to betahistine prodrugs of Formula I, in which R1-R11 are each hydrogen and the amine substituent R12 is non-hydrogen. The synthesis and use of prodrugs for therapeutically active amine-containing compounds have been reviewed in the literature, see Simplício et al., “Prodrugs for amines,” Molecules, 13(3):519-47 (2008), incorporated by reference. Petition 870260106243, dated 10 / 15 / 2026, p. 19 / 106 15 / 35 here, to this patent application, in its entirety.

[0050] Aspects of the present invention further relate to metabolites, prodrugs, and deuterated betahistine analogs to overcome the limitations associated with the original drug. As used herein in this patent application, the term prodrug refers to a betahistine derivative that requires a transformation within the body to release betahistine. In some embodiments, the transformation is an enzymatic transformation. In other embodiments, the transformation is a cyclization transformation. In some other embodiments, the transformation is a combination of an enzymatic transformation and a cyclization reaction. Prodrugs are often, though not necessarily, pharmacologically inactive until they are converted to betahistine.Betahistine prodrugs are designed as conjugates of betahistine and various functional groups or molecular structures, including, but not limited to, amino acids, esters, carbamates, carbonates, phosphoesters, sulfates, glucuronides, peptides, lipids, cyclic structures, self-immolating ligands, polymers, and nanoparticles. Furthermore, the invention also includes codrugs and multiple prodrugs, which represent more complex prodrug strategies. Thus, the present invention also relates to the design, synthesis, and application of betahistine prodrugs and analogs.

[0051] The incorporation of deuterium atoms into the beta-histine structure, replacing one or more hydrogen atoms with deuterium atoms, leads to the production of deuterated beta-histine analogs within the scope of the invention.

[0052] Codrugs (or coprodrugs), as used herein in this patent application, refer to a subclass of prodrugs. Codrugs consist of two pharmacologically active agents linked together, one of which is betahistidine, where each active agent acts as a propharmacy for the other. When administered, the codrug is metabolized, typically through enzymatic or hydrolytic cleavage, to release both active agents. The main advantage of codrugs is to enhance the effects of two drugs, improve their pharmacokinetic profiles, reduce side effects, or increase their solubility and / or stability. Codrugs can be designed for the simultaneous release of both active agents at the same biological site of action or at different sites, depending on the desired therapeutic outcome. Petition 870260106243, dated 10 / 15 / 2026, page 20 / 106 16 / 35

[0053] Multiple prodrug, as used herein in this patent application, refers to a drug that is metabolically transformed into more than one pharmacologically active molecule. Essentially, one prodrug molecule can give rise to multiple active drug molecules after metabolism.

[0054] Nanoparticle prodrugs, as used herein in this patent application, refer to drug molecules that have been incorporated or encapsulated in nanoparticles to achieve controlled drug release, increased solubility, improved bioavailability, targeted drug release, and / or a combination thereof. These nanoparticles may be composed of various materials, such as lipids (liposomes), proteins, metals, or polymers, as is known in the art. The prodrug is generally transformed into its active form as soon as it reaches its target site or in response to specific triggers such as pH, enzymes, or other stimuli.

[0055] Betahistine prodrugs are intended to modify the pharmacokinetics of the original betahistine drug, increasing its stability, absorption, and half-life, thereby reducing dosing frequency and improving patient adherence to treatment regimens. In addition, by leveraging different prodrug strategies, these new compounds mitigate the gastrointestinal side effects observed with betahistine, improving the overall safety and tolerability profile of the medication.

[0056] Optional substituents may be selected from alkyl, cycloalkyl, aryl, heteroaryl, hydroxy, alkoxy, halogen and the like without limitation, as well as conjugates and functional groups, solubilizing groups, lipid groups and the like to optimize pharmacokinetic and other properties.

[0057] As used herein in this patent application, unless otherwise noted, alkyl and / or aliphatic, whether used alone or as part of a substituent group, refers to straight and branched carbon chains with 1 to 20 carbon atoms or any number within this range, for example, 1 to 6 carbon atoms or 1 to 4 carbon atoms. The designated numbers of carbon atoms (e.g., C1-6) will refer independently to the number of carbon atoms in an alkyl moiety or to the alkyl moiety of a larger alkyl-containing substituent. Non-limiting examples of alkyl groups include methyl, Petition 870260106243, dated 10 / 15 / 2026, p. 21 / 106 17 / 35 ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl and the like.

[0058] As used herein in this patent application, “cycloalkyl,” whether used alone or as part of another group, refers to a non-aromatic carbon-containing ring, including cyclized alkyl, alkenyl, and alkynyl groups, for example, having from 3 to 14 carbon atoms in the ring, preferably 3 to 7 or 3 to 6 carbon atoms in the ring, or even 3 to 4 carbon atoms in the ring, and optionally containing one or more (e.g., 1, 2, or 3) double or triple bonds. Cycloalkyl groups may be monocyclic (e.g., cyclohexyl) or polycyclic (e.g., containing fused, bridging, and / or spiro ring systems), where the carbon atoms are located inside or outside the ring system. Any suitable ring position of the cycloalkyl group may be covalently linked to the defined chemical structure. Cycloalkyl rings may be optionally substituted.Non-limiting examples of cycloalkyl groups include: cyclopropyl, 2-methyl-cyclopropyl, cyclopropenyl, cyclobutyl, 2,3-dihydroxycyclobutyl, cyclobutenyl, cyclopentyl, cyclopentenyl, cyclopentadienyl, cyclohexyl, cyclohexenyl, cycloheptyl, cyclooctanyl, decalinyl, 2,5-dimethylcyclopentyl, 3,5-dichlorocyclohexyl, 4hydroxycyclohexyl, 3,3,5-trimethylcyclohex-1-yl, octahydropentalenyl, octahydro-1Hindenyl, 3a, 4,5,6,7,7a-hexahydro-3H-inden-4-yl, decahydroazulenyl; biciclo[6.2.0] decanyl, decahydronaphthalenyl and dodecahydro-1H-fluorenyl. The term “cycloalkyl” also includes carbocyclic rings, which are bicyclic hydrocarbon rings, non-limiting examples of which include bicyclo[2.1.1]hexanyl, bicyclo[2.2.1]heptanyl, bicyclo[3.1.1]heptanyl, 1,3-dimethyl[2.2.1]heptan-2-yl, bicyclo[2.2.2]octanyl, and bicyclo[3.3.3]undecanyl.

[0059] The term “aryl,” whether used alone or as part of another group, is defined herein, in this patent application, as an unsaturated 6-membered monocyclic aromatic ring or an unsaturated 10- to 14-membered polycyclic aromatic ring. Aryl rings may be, for example, phenyl or naphthyl rings, each optionally substituted with one or more moieties capable of replacing one or more hydrogen atoms. Non-limiting examples of aryl groups include: phenyl, naphthyl-1-yl, naphthyl-2-yl, 4-fluorophenyl, 2-hydroxyphenyl, 3-methylphenyl, 2-amino-4-fluorophenyl, 2-(N,N-diethylamino)phenyl, 2-cyanophenyl, 2,6-di-tert-butylphenyl, 3-methoxyphenyl, 8-hydroxynaphthyl-2-yl, 4,5-dimethoxynaphthyl-1-yl, and 6-cyano-naphthyl-1-yl. Aryl groups also include, for example, phenyl naphthyl rings. Petition 870260106243, dated 10 / 15 / 2026, p. 22 / 106 18 / 35 fused with one or more saturated or partially saturated carbon rings (e.g., bicyclo[4.2.0]octa-1,3,5-trienyl, indanyl), which may be substituted at one or more carbon atoms of the aromatic and / or saturated or partially saturated rings.

[0060] The term “heteroaryl,” whether used alone or as part of another group, is defined herein, in this patent application, as one or more rings having from 5 to 20 atoms, wherein at least one atom in at least one ring is a heteroatom chosen from nitrogen (N), oxygen (O), or sulfur (S), and wherein at least one of the rings that includes a heteroatom is aromatic. In heteroaryl groups that include 2 or more fused rings, the ring that does not contain a heteroatom may be a carbocycle (e.g., 6,7-Dihydro-5H-cyclopentapyrimidine) or an aryl group (e.g., benzofuranyl, benzothiophenyl, indolyl). Exemplary heteroaryl groups have from 5 to 14 ring atoms and contain from 1 to 5 ring heteroatoms independently selected from nitrogen (N), oxygen (O), or sulfur (S). One or more N or S atoms in a heteroaryl group can be oxidized. Heteroaryl groups can be substituted.Non-limiting examples of heteroaryl rings containing a single ring include: 1,2,3,4-tetrazolyl, [1,2,3]triazolyl, [1,2,4]triazolyl, triazinyl, thiazolyl, 1H-imidazolyl, oxazolyl, furanyl, thiophenoyl, pyrimidinyl, 2-phenylpyrimidinyl, pyridinyl, 3-methylpyridinyl and 4-dimethylaminopyridinyl. Non-limiting examples of heteroaryl rings containing 2 or more fused rings include: benzofuranyl, benzothiophenyl, benzoxazolyl, benzthiazolyl, benztriazolyl, cinolinyl, naphthyridinyl, phenanthridinyl, 7H-purinyl, 9H-purinyl, 6-amino-9H-purinyl, 5H-pyrrolo[3,2-d]pyrimidinyl, 7 H-pyrrolo[2,3-d]pyrimidinyl, pyrido[2,3-d]pyrimidinyl, 2-phenylbenzo[d]thiazolyl, 1H-indolyl, 4,5,6,7-tetrahydro-1-H-indolyl, quinoxalinyl, 5-methylquinoxalinyl, quinazolinyl, quinolinyl, 8-hydroxyquinolinyl, and isoquinolinyl.

[0061] As used herein in this patent application, unless a specific definition is otherwise provided, the substituted term refers to a group substituted with deuterium, a halogen (-F, -Cl, -Br, -I), a hydroxyl group (-OH), an amino group (-NH2), a carboxyl group (-CO2H), a substituted or unsubstituted C1C10 amine group, a nitro group (-NO2), a C1-C10 alkyl group, a C3-C10 cycloalkyl group, a C6-C12 aryl group, a C1-C10 alkoxy group, a C1 to C10 trifluoroalkyl group, such as a trifluoromethyl group (-CF3) and the like, or a cyano group (-CN) instead of at least one hydrogen of a group or Petition 870260106243, dated 10 / 15 / 2026, page 23 / 106 19 / 35 Substituent compound. Exemplary substituents include alkyl, alkylidenyl, alkylcarboxy, alkoxy, alkenyl, alkenylcarboxy, alkenyloxy, aryl, aryloxy, alkylaryl, alkylaryloxy, -OH, amide, carboxamide, carboxy, sulfonyl, =O, =S, -NO2, halogen, haloalkyl, optionally substituted fused saturated or unsaturated rings, S(O)R, -SO3R, -SR, -NRR', -OH, -CN, -C(O)R, -OC(O)R, -NHC(O)R, -(CH2)nCO2R or -(CH2)nC0NRR' where n is 0-4, and where R and R' are independently H, alkyl, aryl or alkylaryl. Substituents also include the replacement of a carbon atom with one or more associated hydrogen atoms.

[0062] In one aspect, betahistine prodrugs of the invention are composed of Formula I: Formula 1 in which, R1-R4 are each selected independently as either hydrogen or deuterium; R5-R7 are each selected independently as either hydrogen or deuterium; R9-R11 are each independently selected from either hydrogen or deuterium; and R12 is selected from hydrogen, deuterium, optionally substituted alkyl, optionally substituted aryl, -C(O)Ri3, -S(O)Ri3, -S(O)2Ri3, C(O)ORi3, -P(O)2ORi3, -N(Ri3)(Ri4), wherein R13 and R14 are independently selected from hydrogen, optionally substituted alkyl or optionally substituted aryl, provided that at least one of R1-R12 is different from hydrogen or deuterium; and pharmaceutically acceptable salts thereof.

[0063] In one aspect of the invention, betahistine is conjugated to an amino acid Petition 870260106243, dated 10 / 15 / 2026, page 24 / 106 20 / 35 of, so that R12 comprises at least one amino acid in the betahistine prodrug compound of Formula I.

[0064] In betahistine prodrug compounds of Formula I, at least one amino acid from R12 is selected from glycine, alanine, valine, leucine, isoleucine, methionine, phenylalanine, tyrosine, tryptophan, proline, serine, threonine, cysteine, asparagine, glutamine, arginine, histidine, lysine, aspartate (also known as aspartic acid), glutamate (also known as glutamic acid), selenocysteine, and pyrrolysine.

[0065] In betahistine prodrug compounds of Formula I, R12 may comprise a non-amino acid, such as ornithine, taurine, citrulline, carnitine, creatine, gamma-aminobutyric acid (GABA), beta-alanine, hydroxyproline, 5-hydroxytryptophan, betaine, choline, inositol, anserine, carnosine, agmatine, sarcosine, polyamines (such as spermine and spermidine), alpha-ketoglutarate, NADH and coenzyme Q10.

[0066] In betahistine prodrug compounds of Formula I, R12 may comprise an amino acid conjugated to an acetyl group, an ester group, an amino acid ester group, a carbamate group, a carbonate group, a phosphoester group, a glucuronide group, a peptide group, a lipid group, a cyclic group, a self-immolating linker group, a polymer group and the like.

[0067] In betahistine prodrug compounds of Formula I, when R12 comprises an ester group, the ester group is preferably selected from methyl, ethyl, propyl, isopropyl, butyl, isobutyl, pentyl, hexyl, heptyl, octyl, nonyl or decyl esters.

[0068] In betahistine prodrug compounds of Formula I, when R12 comprises an amino acid ester group, the amino acid ester group is preferably selected from alanine methyl ester, valine methyl ester, leucine methyl ester, isoleucine methyl ester, methionine methyl ester, phenylalanine methyl ester, tryptophan methyl ester, proline methyl ester, glycine methyl ester, serine methyl ester, threonine methyl ester, cysteine ​​methyl ester, tyrosine methyl ester, asparagine methyl ester, glutamine methyl ester, aspartic acid methyl ester, glutamic acid methyl ester, lysine methyl ester, arginine methyl ester, or histidine methyl ester. Petition 870260106243, dated 10 / 15 / 2026, page 25 / 106 21 / 35 na.

[0069] In betahistine prodrug compounds of Formula I, when R12 comprises a carbamate ester group, the carbamate ester group is preferably selected from methyl carbamate, ethyl carbamate, propyl carbamate, isopropyl carbamate, butyl carbamate, sec-butyl carbamate, isobutyl carbamate, tert-butyl carbamate, pentyl carbamate, hexyl carbamate, cyclopentyl carbamate, cyclohexyl carbamate, benzyl carbamate, phenethyl carbamate or phenyl carbamate.

[0070] Nos compostas de profármacos de beta-histina de Fórmula I, quando R12 compreende um grupo éster de carbonato, o grupo éster de carbonato é preferencialmente selecionado entre carbonato de dimetila, carbonato dietila, carbonato de dipropila, carbonato de di-isopropila, carbonato de dibutila, carbonato de di-isobutila, carbonato de dipentila, carbonato de di-hexila, carbonato de diciclopentila, carbonato de diciclo-hexila, carbonato de dibenzila, carbonato de difenetila ou carbonato de difenila.

[0071] Our beta-histine chemical compounds of Formula I, when R12 comprises a phosphoester group, or phosphoester group is preferentially selected among dimethyl phosphite, diethyl phosphite, dipropyl phosphite, di-isopropyl phosphite, dibutyl phosphite, di-isobutyl phosphite, dipentyl phosphite, di-hexyl phosphite, dicyclopentyl phosphite, dicyclo-hexyl phosphite, dibenzyl phosphite, diphenethyl phosphite or diphenyl phosphite.

[0072] In betahistine prodrug compounds of Formula I, when R12 comprises a glucuronide group, the glucuronide group is preferably selected from β-D-glucuronic acid methyl ester, β-D-glucuronic acid ethyl ester, β-D-glucuronic acid propyl ester, β-D-glucuronic acid butyl ester, β-D-glucuronic acid pentyl ester, β-D-glucuronic acid hexyl ester, β-D-glucuronic acid heptyl ester, β-D-glucuronic acid octyl ester, β-D-glucuronic acid nonyl ester, β-D-glucuronic acid decyl ester, β-D-glucuronic acid undecyl ester, dodecyl ester of β-D-glucuronic acid β-D-glucuronic acid, tridecyl ester of β-D-glucuronic acid, tetradecyl ester of β-D-glucuronic acid, or pentadecyl ester of β-D-glucuronic acid.

[0073] In betahistine prodrug compounds of Formula I, when R12 comprises a peptide group, the peptide group is preferentially selected Petition 870260106243, dated 10 / 15 / 2026, page 26 / 106 22 / 35 among glycine, alanine, valine, leucine, isoleucine, methionine, phenylalanine, tryptophan, proline, serine, threonine, cysteine, tyrosine, asparagine, glutamine, aspartic acid, glutamic acid, lysine, arginine, histidine and any possible di-, tri-, tetra-, penta-, hexa-, hepta-, octa-, nona-, deca-, undeca-, dodeca-, trideca-, tetradeca-, pentadeca- peptide, or a combination of said amino acids.

[0074] In betahistine prodrug compounds of Formula I, when R12 comprises a lipid group, the lipid group is preferably selected from lauric acid, myristic acid, palmitic acid, stearic acid, arachidic acid, behenic acid, lignoceric acid, cerotic acid, montanic acid, melissic acid, palmitoleic acid, oleic acid, vaccenic acid, linoleic acid, alpha-linolenic acid, gamma-linolenic acid, stearidonic acid, arachidonic acid, eicosapentaenoic acid, docosahexaenoic acid and all possible mono-, di-, tri-, tetra-, penta-, hexa-, hepta-, octa-, nona-, deca-, undeca-, dodeca-, trideca-, tetradeca-, pentadeca- and lipid combinations of said lipid groups.

[0075] In betahistine prodrug compounds of Formula I, when R12 comprises a cyclic group, the cyclic group is preferably selected from cyclopropane, cyclobutane, cyclopentane, cyclohexane, cycloheptane, cyclooctane, cyclononane, cyclodecane, cycloundecane, cyclododecane, cyclotridecane, cyclotetradecane, cyclopentadecane and all possible mono-, di-, tri-, tetra-, penta-, hexa-, hepta-, octa-, nona-, deca-, undeca-, dodeca-, trideca-, tetradeca-, pentadeca- cyclic combinations of said cyclic groups.

[0076] In betahistine prodrug compounds of Formula I, when R12 comprises a self-immolating linker group, the self-immolating linker group is preferably selected from para-nitrobenzyl ligands, ortho-nitrobenzyl ligands, aromatic ligands, aliphatic ligands, heterocyclic ligands, carbamate ligands, carbonate ligands, amide ligands, urea ligands, thiourea ligands, ester ligands, thioester ligands, disulfide ligands, sulfonamide ligands and all possible combinations of mono-, di-, tri-, tetra-, penta-, hexa-, hepta-, octa-, nona-, deca-, undeca-, dodeca-, trideca-, tetradeca-, pentadecade self-immolating ligands of said self-immolating linker groups.

[0077] In betahistine prodrug compounds of Formula I, when R12 comprises a polymeric group, the polymeric group is preferentially selected Petition 870260106243, dated 10 / 15 / 2026, p. 27 / 106 23 / 35 blended between polyethylene glycol (PEG), polylactic acid (PLA), polyglycolic acid (PGA), polylactic-co-glycolic acid (PLGA), polyvinylpyrrolidone (PVP), polyvinyl alcohol (PVA), chitosan, hyaluronic acid, dextran and all possible mono-, di-, tri-, tetra-, penta-, hexa-, hepta-, octa-, nona-, deca-, undeca-, dodeca-, trideca-, tetradeca-, pentadeca- polymeric combinations of said polymeric groups.

[0078] Betahistine and its salts, analogues, metabolites, prodrugs, derivatives, metabolites, cocrystals, modifications, solvates, hydrates, isotopes, tautomers, esters, polymorphs or stereoisomers can be incorporated into lipid nanoparticles, wherein the nanoparticle is selected from liposomes, micelles, dendrimers, nanotubes, nanoemulsions, nanospheres, nanoporous materials, quantum dots, nanoshells, nanocapsules and all possible combinations of mono-, di-, tri-, tetra-, penta-, hexa-, hepta-, octa-, nona-, deca-, undeca-, dodeca-, trideca-, tetradeca-, pentadeca- of said nanoparticles.

[0079] The invention includes betahistine, and its salts, analogues, metabolites, prodrugs, derivatives, metabolites, cocrystals, modifications, solvates, hydrates, isotopes, tautomers, esters, polymorphs or stereoisomers, in which betahistine is conjugated or associated with a targeting moiety, the targeting moiety facilitating the release of the prodrug compound to the central nervous system (CNS). The targeting moiety is preferentially selected from among transferrin, lactoferrin, melanotransferrin, receptor-specific antibodies, receptor-specific peptides, receptor-specific proteins, receptor-specific aptamers, and all possible combinations of mono-, di-, tri-, tetra-, penta-, hexa-, hepta-, octa-, nona-, deca-, undeca-, dodeca-, trideca-, tetradeca-, pentadeca- of said targeting moieties.

[0080] The invention includes betahistine, its salts, analogues, metabolites, prodrugs, derivatives, metabolites, cocrystals, modifications, solvates, hydrates, isotopes, tautomers, esters, polymorphs or stereoisomers, wherein betahistine is activated or released from the prodrug by enzymatic cleavage, the enzymatic cleavage being facilitated by an enzyme selected from esterases, amidases, proteases, kinases, phosphatases, glycosidases, lipases, nucleases, and all possible combinations of mono-, di-, tri-, tetra-, penta-, hexa-, hepta-, octa-, nona-, deca-, undeca-, dodeca-, trideca-, tetradeca-, pentadeca- of said enzymes. Petition 870260106243, dated 10 / 15 / 2026, page 28 / 106 24 / 35

[0081] The invention includes betahistine, its salts, analogues, metabolites, prodrugs, derivatives, metabolites, cocrystals, modifications, solvates, hydrates, isotopes, tautomers, esters, polymorphs or stereoisomers, wherein betahistine is conjugated with a capping group, the capping group being cleavable under certain conditions to release the active betahistine, the capping group preferably selected from nitrobenzyl groups, coumarinyl methyl groups, dimethoxybenzoinyl groups, bromohydroxyquinoline groups, 7-nitroindolinyl groups and all possible combinations of mono-, di-, tri-, tetra-, penta-, hexa-, hepta-, octa-, nona-, deca-, undeca-, dodeca-, trideca-, tetradeca-, pentadeca- capping groups.

[0082] The invention includes betahistine prodrugs, wherein betahistine is formulated as a peptide prodrug comprising a phosphate ester linked to an amino acid ester, said amino acid ester being selected from alanine, valine, leucine, isoleucine, methionine, phenylalanine, tryptophan, serine, threonine, cysteine, tyrosine, asparagine, glutamine, glycine, proline, histidine, arginine, lysine, aspartic acid, glutamic acid and all possible combinations of mono-, di-, tri-, tetra-, penta-, hexa-, hepta-, octa-, nona-, deca-, undeca-, dodeca-, trideca-, tetradeca-, pentadeca- of said amino acid esters.

[0083] The invention includes betahistine, its salts, analogues, metabolites, prodrugs, derivatives, metabolites, cocrystals, modifications, solvates, hydrates, isotopes, tautomers, esters, polymorphs or stereoisomers, wherein betahistine is formulated as a co-drug in combination with another therapeutically active agent, said therapeutically active agent selected from among a monoamine oxidase inhibitor (MAOI) such as selegiline, a combination of MAOIs, histamine, a histamine analogue, a histamine derivative, L-Histidine, HTMT (histamine N-methyltransferase), or a histamine precursor or prodrug, a glutamate modulating agent such as memantine, N-acetylcysteine, ketamine, D-cycloserine or a combination thereof, among others.

[0084] The invention includes betahistine, its salts, analogues, metabolites, prodrugs, derivatives, metabolites, cocrystals, modifications, solvates, hydrates, isotopes, tautomers, esters, polymorphs or stereoisomers, wherein betahistine is conjugated with one or more other betahistine prodrugs, each of said other prodrugs being selected from the group consisting of: prodrugs of Petition 870260106243, dated 10 / 15 / 2026, p. 29 / 106 25 / 35 esters, amino acid esters, carbamate prodrugs, carbonate prodrugs, phosphoester prodrugs, sulfate conjugates, glucuronide conjugates, peptide conjugates, lipid conjugates, cyclic prodrugs, self-immolating ligand prodrugs, polymer conjugates, nanoparticle prodrugs, codrugs and all possible combinations of mono-, di-, tri-, tetra-, penta-, hexa-, hepta-, octa-, nona-, deca-, undeca-, dodeca-, trideca-, tetradeca-, pentadeca- of said additional prodrugs.

[0085] The range of prodrug classes considered in this invention includes ester prodrugs and amino acid ester prodrugs, which are expected to improve the bioavailability and stability of the drug. Carbamate prodrugs and carbonate prodrugs are included for their potential to offer controlled-release properties, increasing the duration of the therapeutic effect.

[0086] Phosphoester prodrugs and sulfate conjugates are employed considering their potential to increase solubility and bioavailability, while glucuronide conjugates, which are commonly used in drug detoxification, are expected to help improve the safety profile of betahistine.

[0087] Peptide-lipid conjugates are expected to enhance cellular uptake and targeted delivery, while cyclic prodrugs could potentially offer improved stability and controlled release. Self-immolating ligand prodrugs have the added benefit of releasing the active drug as well as a biologically active starting group, which could provide synergistic effects. The invention also explores the development of polymer and nanoparticle prodrug conjugates, which can increase solubility, control drug release, and improve targeted drug delivery. The scope of the invention also extends to the design of codrugs and multiple prodrugs, which allow the simultaneous release of two or more drugs, potentially offering synergistic therapeutic effects or mitigating side effects.

[0088] Each class of prodrugs under this invention has been designed to provide distinct advantages over the original betahistine drug, including improvements in stability, solubility, absorption, and half-life, along with Petition 870260106243, dated 10 / 15 / 2026, page 30 / 106 26 / 35 with reduced side effects.

[0089] In addition, the invention involves methods of synthesizing these prodrugs and details pharmaceutical compositions comprising these prodrugs together with pharmaceutically acceptable carriers.

[0090] The present invention is useful for treating and / or reducing OCD symptoms, as shown by a reduced Y-BOCS score, and for treating other OCD disorders, as shown by the reduction in the severity measurements of the corresponding symptoms.

[0091] The present invention is useful for treating and / or reducing symptoms of tic disorders by reducing tics, as demonstrated by, for example, the Yale Global Tic Severity Scale.

[0092] The present invention is useful for treating and / or reducing symptoms of amyotrophic lateral sclerosis, as shown by, for example, prolonged survival.

[0093] The present invention is useful for treating and / or reducing the symptoms of diseases related to glutamate excitotoxicity, as shown by, for example, prolonged survival.

[0094] The present invention is useful for treating and / or reducing symptoms of autism spectrum disorders, as shown by a decrease in the score on the Aberrant Behavior Scale (ABC) or a decrease within one or more subscales within the ABC, including the subscales of Irritability, Hyperactivity, Lethargy / Withdrawal, Stereotypy, and Inappropriate Speech.

[0095] The present invention is useful for treating and / or reducing symptoms of autism spectrum disorders, as shown by a decrease in the Repetitive Behavior Scale (RBS) score or a decrease within one or more subscales within the RBS, including stereotypies, self-injurious behaviors, compulsions, rituals, insistence on sameness, and subscales of restricted behaviors.

[0096] The following examples are presented below to illustrate methods and results according to the disclosed subject matter. These examples are not intended to be inclusive of all aspects of the subject matter disclosed herein in this patent application, but rather to illustrate methods, compositions, and results representative of the subject matter. Petition 870260106243, dated 10 / 15 / 2026, p. 31 / 106 27 / 35 alternatives. These examples are not intended to exclude equivalents and variations of the present invention, which are evident to one skilled in the art. Background implicating the modulation of basal ganglia histamine in the pathophysiology of OCD and Tourette syndrome.

[0097] Past work on the pathophysiology of obsessive-compulsive disorder (OCD) has focused on the dysregulation of the basal ganglia system and the neurotransmitters serotonin, dopamine, and glutamate, and the pharmacotherapeutic approaches that modulate them (Pittenger 2021). More recent studies have begun to examine the role of the histaminergic system in both OCD and Tourette syndrome (Rapanelli and Pittenger 2016, Pittenger 2020). Notably, OCD and Tourette syndrome frequently occur together, are genetically related, and both affect the same circuit in the brain; therefore, both clinicians and scientists studying the pathophysiology often consider them together. This line of research stems from the discovery of a rare mutation in the histidine decarboxylase (HDC) gene, which is necessary for histamine biosynthesis, in a family with a high rate of both OCD and Tourette syndrome (Ercan-Sencicek, Stillman et al. 2010).A mouse model recapitulating this genetic abnormality exhibits repetitive, compulsion-like behaviors (see below for further discussion of mouse models of OCD and Tourette syndrome) (Baldan, Williams et al. 2014). Ongoing work in mouse models has further elucidated the important role of histamine in modulating the basal ganglia system (Rapanelli, Frick et al. 2016, Rapanelli, Frick et al. 2017, Xu and Pittenger 2023), which is implicated in both OCD and Tourette syndrome, and the ability of histamine signaling manipulations to regulate compulsion and repetitive tic-like behaviors (Rapanelli, Frick et al. 2017, Rapanelli, Frick et al. 2017, Verma, Agrawal and Jain 2018, Zhang, Peng et al. 2020). Preclinical evidence showing that betahistine mitigates compulsive and stereotypical tic-like behavior in a mouse model.

[0098] High levels of self-grooming and other repetitive stereotypical behaviors have been used in several genetic and other model systems to capture compulsive behavior (Greer and Capecchi 2002, Welch, Lu et al. 2007, Petition 870260106243, dated 10 / 15 / 2026, page 32 / 106 28 / 35 Chen, Tvrdic et al. 2010, Shmelkov, Hormigo et al. 2010, Ahmari, Spellman et al. 2013, Baldan, Williams et al. 2014, Xu, Li et al. 2015, Zike, Chohan et al. 2017, Nagarajan, Jones et al. 2018, Ahmed, Jayakumar et al. 2019, Escobar, Martinez-Pinto et al. 2021, Passwords, Schneeberger et al. 2021). OCD and Tourette syndrome are exacerbated in patients by amphetamine (Shakeri, Farnia et al. 2016); similarly, compulsive self-grooming and stereotypy are increased in camundongo by the stimulus with amphetamine, a fact that has been used in the analysis of several camundongo models of OCD and Tourette syndrome (Baldan, Williams et al. 2014, Zike, Chohan et al., 2017, E. Martinez-Sco, Martin et al., 2017). al. 2021).In the mutant HDC model of OCD and Tourette syndrome, repetitive, compulsive self-grooming is observed following amphetamine stimulation and is mitigated by experimental histamine replacement, demonstrating the usefulness of the amphetamine stimulation model for capturing neural and behavioral events relevant to OCD in a mouse system (Baldan, Williams et al. 2014).

[0099] This model system was used to test the ability of betahistine to mitigate compulsion and tic-like behaviors in two experiments in mice. EXAMPLE 1

[00100] In a first experiment, male and female C57Bl / 6 mice were injected with either saline or betahistine dihydrochloride (1 mg / kg or 10 mg / kg) 30 minutes before being injected with either saline or amphetamine (8.5 mg / kg). Activity and stereotypy were measured on an open-field apparatus that distinguishes between these two categories of movement by discriminating the associated patterns of infrared beam breaks, as in previous studies using a similar approach (Xu, Kobets et al. 2015, Xu, Li and Pittenger 2016, Rapanelli, Frick et al. 2017). Amphetamine injection is predicted to produce more locomotor behavior in the first 30 minutes after injection and more compulsion-like stereotypy in the second 30 minutes. Anti-OCD pharmacotherapies are predicted to reduce stereotypy.

[00101] As shown in FIG. 1A, amphetamine led to an increase in ambulatory activity scores (i.e., locomotor activation), which was not significantly reduced by pretreatment with betahistine. (Experimental groups Petition 870260106243, dated 10 / 15 / 2026, page 33 / 106 29 / 35 such: Sal / Sal = saline pretreatment, saline stimulation; Sal / Amp = saline pretreatment, amphetamine stimulation; BH1 / Amp = betahistine 1 mg / kg pretreatment, amphetamine stimulation; BH10 / Amp = betahistine 10 mg / kg pretreatment, amphetamine stimulation. (Statistical analysis: 1-way ANOVA, F[3,20] = 6.14, p = 0.004; post-amphetamine treatment groups differed from saline in ** p < 0.01 or * p < 0.05; paired post-hoc comparisons; betahistine pretreatment groups did not differ from the saline / amphetamine group.)

[00102] As shown in FIG. 1B, this effect was, as predicted, limited to the first 30 minutes after injection and was not seen in the second 30 minutes. (Statistical analysis: 4 x 2 mixed ANOVA between / within, time x treatment group interaction, F[3,20] = 26.3, p < 0.0001; paired post-hoc comparisons, all amphetamine-treated groups significantly different from the saline-treated control (green) in the first 30 minutes at ** p < 0.01 or **** p < 0.0001.) Therefore, amphetamine produces an increase in locomotion in the 30 minutes following injection, and this is not altered by pretreatment with betahistine – betahistine does not simply block the effects of amphetamine. This observation is fundamental to the interpretation of the stereotypy measure.

[00103] As shown in 1C, it led to a marked and statistically significant increase in stereotypy; this was completely blocked by pretreatment with betahistine. (Statistical analysis: 1-way ANOVA: F[3,20] = 10.4, p = 0.0002; paired post-hoc comparisons, saline / amphetamine different from saline / saline, p < 0.001; betahistine pretreatment groups different from saline / amphetamine, p < 0.01.)

[00104] As shown in 1D, and as predicted, stereotypy was seen primarily 30–60 minutes after amphetamine stimulation; the same effects were seen in the analysis at both time periods, with accentuated stereotypy in the saline / amphetamine group that was completely blocked by betahistine pretreatment. (Statistical analysis: 4 x 2 mixed ANOVA between / within, time x treatment group interaction, F[3,20] = 2.47, p = 0.091; paired post-hoc comparisons, saline / amphetamine significantly greater than saline / saline, p < 0.001; betahistine pretreatment groups significantly less than saline / amphetamine, p < 0.001). Therefore, betahistine blocks the development Petition 870260106243, dated 10 / 15 / 2026, page 34 / 106 30 / 35 of stereotypies similar to compulsions after amphetamine stimulation, without producing generalized sedation. This corroborates the usefulness of betahistine as a potential treatment for OCD (and Tourette syndrome). EXAMPLE 2

[00105] In a second experiment, amphetamine stimulation was repeated, with or without pretreatment with betahistine dihydrochloride, and the mice were filmed during the subsequent hour. The videos were analyzed using an automated motion capture system (Cleversys HomeCageScan) to quantify locomotor activity and self-grooming. Previous work shows that the self-grooming measure in this system correlates with the manual video self-grooming score by a qualified observer, validating this measure of mouse self-grooming (Xu, Kobets et al. 2015); elevated self-grooming in mice has been validated as a model of OCD in multiple previous studies (Greer and Capecchi 2002, Welch, Lu et al. 2007, Chen, Tvrdik et al. 2010, Shmelkov, Hormigo et al. 2010, Xu, Li et al. 2015).

[00106] As shown in Figure 2A, locomotor activation after amphetamine was limited in the HomeCageScan environment, which is less precise in its measurement of locomotion than the open-field apparatus used in Example 1. (Statistic: 1-way ANOVA, F[3,20] = 1.24, p = 0.32). Figure 2B shows that, as in Example 1, the increase in locomotion was most clearly evident in the first 30 minutes after amphetamine stimulation; this was not altered by pretreatment with betahistine at either 1 mg / kg or 10 mg / kg. (Statistical analysis: 4 x 2 mixed ANOVA between-within, time x treatment group interaction, F[3,20] = 10.1, p = 0.0003; paired post-hoc comparisons, all amphetamine-treated groups significantly different from the salt / salt group at ** p < 0.01 or *** p < 0.001 in the first 30 minutes after amphetamine, with no effect of betahistine pretreatment.)Therefore, as in Example 1, amphetamine induces an increase in locomotion, and betahistine does not nonspecifically block the effects of amphetamine or cause general sedation.

[00107] As shown in Figure 2C, amphetamine stimulation led to increased self-cleaning; this was mitigated by pretreatment with betahistine at 10 mg / kg, but not with 1 mg / kg, indicating a dose-response relationship. (Analysis this Petition 870260106243, dated 10 / 15 / 2026, page 35 / 106 31 / 35 Statistics: One-way ANOVA, F[3,20] = 6.53, p = 0.0003; paired post-hoc comparisons, the salt / amphetamine and BH1 / amphetamine groups showed more self-cleaning than salt / salt, p < 0.05; BH10 / amphetamine showed reduced self-cleaning compared to both salt / amphetamine and BH1 / amphetamine, p < 0.05.)

[00108] Self-cleaning was specifically elevated in the second 30 minutes after injection, as the stereotypy in the experiment shown in Figure 1, and this effect was blocked by pretreatment with betahistine at a dose of 10 mg / kg; again, the effect of pretreatment with betahistine at 1 mg / kg was limited and not statistically significant. (Statistical analysis: 4 x 2 mixed ANOVA within, main effect of group, F[3,20] = 7.3, p = 0.003; paired post-hoc comparisons, saline / amphetamine group vs saline / saline group at the second 30 minutes, p < 0.01; BH10 / amphetamine group vs saline / amphetamine group at the second 30 minutes, p < 0.05). Therefore, pretreatment with betahistine at 10 mg / kg blocks the induction of compulsive self-cleaning produced by amphetamine stimulation, without producing nonspecific sedation. Clinical response to betahistine in an individual with treatment-refractory OCD. EXAMPLE 3

[00109] The case of an individual with treatment-resistant OCD who showed marked improvement after treatment with betahistine dihydrochloride has been described. What follows is a clinical description of their case and clinical course by an attending psychotherapist.

[00110] The patient is a man in his early twenties, diagnosed with OCD in early adolescence. During the initial consultation, he exhibited significant functional impairment in daily activities, characterized by recurrent intrusive thoughts and repetitive compulsive behaviors. Previous treatments included pharmacotherapy with SSRIs and second-generation neuroleptics, with little improvement; pharmacotherapy was discontinued due to lack of benefit and problematic side effects, including emotional blunting, brain fog, hyperprolactinemia, and weight gain. The severity of symptoms was not assessed using standardized clinical measures, but was considered to be in the severe range.

[00111] The patient was administered betahistine dihydrochloride (16 mg twice daily for Petition 870260106243, dated 10 / 15 / 2026, page 36 / 106 Betahistine was prescribed (32 / 35 weeks) by a neurologist for the treatment of trauma-induced vertigo. Symptoms of OCD were markedly improved, but returned days after betahistine was discontinued. Betahistine treatment was restarted at a lower dose (8 mg daily, then 8 mg twice daily) and symptoms were again markedly reduced. This treatment was then continued for several years, with ongoing benefit, including a reduction in the frequency and intensity of compulsive behaviors and obsessive thoughts. On several occasions when betahistine was discontinued, symptoms relapsed; when betahistine was restarted, symptoms improved again. This improvement in symptoms was accompanied by an improvement in occupational and social function, as evidenced by a ~20% improvement in university grades and an improved ability to maintain social and romantic relationships.

[00112] This sustained improvement in function is shown in FIG. 3, which illustrates medical school grades before and after treatment with betahistine. Medical school grades where this individual was enrolled during this period are numerical on a scale of 1 to 20. For the 8 semesters prior to taking betahistine, grades ranged from 12.31 to 14.81 (mean 13.5, standard deviation 0.73). For the 4 semesters after starting betahistine treatment, grades ranged from 16.04 to 17.49 (mean 16.9, standard deviation 0.65). This difference was highly statistically significant (two-tailed independent samples t-test: p < 0.0001).

[00113] Throughout this application, several publications are referenced by author name and date, or by patent number or patent publication number. Disclosures from these publications are incorporated in their entirety into this application by reference, in order to more fully describe the state of the art as known to those skilled in the art at the date of the invention described and claimed herein in this patent application. However, citation of a reference herein in this patent application shall not be deemed to be an acknowledgment that such reference is prior art to the present invention.

[00114] Those skilled in the art will recognize or be able to determine, using no more than routine experimentation, numerous equivalents to the specific procedures described herein in this patent application. The aforementioned Petition 870260106243, dated 10 / 15 / 2026, p. 37 / 106 33 / 35 equivalents are considered to be within the scope of this invention and are covered by the claims that follow. For example, pharmaceutically acceptable salts other than those specifically disclosed in the description and examples herein in this patent application may be employed. Furthermore, it is intended that specific items within lists of items, or subgroups of items within larger groups of items, may be combined with other specific items, subgroups of items, or larger groups of items, whether or not there is a specific disclosure herein in this patent application identifying such a combination. REFERENCES [1] Ahmari, et al., “Repeated cortico-striatal stimulation generates persistent OCD-like behavior.” Science, 340(6137):1234-1239 (2013). [2] Ahmed, et al., “Pharmacological antagonism of histamine H2R ameliorated L-DOPA-induced dyskinesia via normalization of GRK3 and by suppressing FosB and ERK in PD.” Neurobiol Aging, 81:177-189 (2019). [3] Baldan, et al., “Histidine decarboxylase deficiency causes Tourette syndrome: parallel findings in humans and mice,” Neuron, 81(1):77-90 (2014). [4] Chen, et al., “Hematopoietic origin of pathological grooming in Hoxb8 mutant mice,” Cell, 141(5):775-785 (2010). [5] Ercan-Sencicek, er al., “L-histidine decarboxylase and Tourette's syndrome, N. Engl. J. Med., 362(20):1901-1908 (2010). [6] Escobar, et al., “Altered Grooming Syntax and AmphetamineInduced Dopamine Release in EAAT3 Overexpressing Mice,” Front Cell Neurosci., 15:661478 (2021). [7] Greer, J. M. et al., “Hoxb8 is required for normal grooming behavior in mice,” Neuron, 33(1):23-34 (2002). [8] Nagarajan, et al., “Corticostriatal circuit defects in Hoxb8 mutant mice,” Mol. Psychiatry, 23(9):1868-1877 (2018). [9] Parolari, et al., “Functional analysis of distinct populations of subthalamic nucleus neurons on Parkinson's disease and OCD-like behaviors in mice,” Mol. Psychiatry, 26(11):7029-7046 (2021). Petição 870260106243, de 15 / 10 / 2026, pág. 38 / 106 34 / 35

[10] Pittenger, C., “The histidine decarboxylase model of tic pathophysiology: a new focus on the histamine H(3) receptor,” Br. J. Pharmacol., 177(3):570-579 (2020).

[11] Pittenger, C., “Pharmacotherapeutic Strategies and New Targets in OCD,” Curr. Top. Behav. Neurosci., 49:331-384 (2021).

[12] Rapanelli, et al., “Histamine modulation of the basal ganglia circuitry in the development of pathological grooming,” Proc. Natl. Acad. Sci., USA, 114(25):6599-6604 (2017).

[13] Rapanelli, et al., “Histamine H3R receptor activation in the dorsal striatum triggers stereotypies in a mouse model of tic disorders,” Transl. Psychiatry, 7(1): e1013 (2017).

[14] Rapanelli, et al., “The Histamine H3 Receptor Differentially Modulates Mitogen-activated Protein Kinase (MAPK) and Akt Signaling in Striatonigral and Striatopallidal Neurons,” J. Biol. Chem., 291(40):21042-21052 (2016).

[15] Rapanelli, et al., “Histamine and histamine receptors in Tourette syndrome and other neuropsychiatric conditions,” Neuropharmacology, 106:85-90 (2016).

[16] Shakeri, et al., “The prevalence and clinical features of amphetamine-induced obsessive compulsive disorder,” Drug Alcohol Depend., 160:157-162 (2016).

[17] Shmelkov, et al., “Slitrk5 deficiency impairs corticostriatal circuitry and leads to obsessive-compulsive-like behaviors in mice,” Nat. Med., 16(5):598602, 591p following 602 (2010).

[18] Verma, et al., “Enhanced central histaminergic transmission attenuates compulsive-like behavior in mice,” Neuropharmacology, 138:106-117 (2018).

[19] Welch, et al., “Cortico-striatal synaptic defects and OCD-like behaviours in Sapap3-mutant mice,” Nature, 448(7156):894-900 (2007).

[20] Xu, et al., “The histamine H3 receptor modulates dopamine D2 receptor-dependent signaling pathways and mouse behaviors,” J. Biol. Chem., 299(4):104583 (2023). Petição 870260106243, de 15 / 10 / 2026, pág. 39 / 106 35 / 35

[21] Xu, et al., “Targeted ablation of cholinergic interneurons in the dorsolateral striatum produces behavioral manifestations of Tourette syndrome,” Proc. Natl. Acad. Sci., USA, 112(3):893-898 (2015).

[22] Xu, et al., “Histidine decarboxylase knockout mice, a genetic model of Tourette syndrome, show repetitive grooming after induced fear,” Neurosci. Lett., 595:50-53 (2015).

[23] Xu, et al., “Ablation of fast-spiking interneurons in the dorsal striatum, recapitulating abnormalities seen post-mortem in Tourette syndrome, produces anxiety and elevated grooming,” Neuroscience, 324:321-329 (2016).

[24] Zhang, et al., “Targeting presynaptic H3 heteroreceptor in nucleus accumbens to improve anxiety and obsessive-compulsive-like behaviors,” Proc. Natl. Acad. Sci., USA, 117(50) 32155-32164 (2020).

[25] Zike, et al., “OCD candidate gene SLC1A1 / EAAT3 impacts basal ganglia-mediated activity and stereotypic behavior,” Proc. Natl. Acad. Sci., USA, 114(22): 5719-5724 (2017).

Claims

1. A method for treating a related obsessive-compulsive disorder (OCD), characterized by the fact that it comprises administering to an individual in need thereof a therapeutically effective amount of betahistine or a pharmaceutically acceptable prodrug, derivative, metabolite, cocrystal, modification, salt, free acid or base, solvate, hydrate, isotope, tautomer, ester, polymorph or stereoisomer thereof.

2. Method according to claim 1, characterized in that TOCR is selected from the group consisting of obsessive-compulsive disorder (OCD), hoarding disorder, trichotillomania (hair-pulling disorder), excoriation disorder (skin picking), body dysmorphic disorder, substance / medication-induced and related obsessive-compulsive disorder, obsessive-compulsive disorder due to another medical condition.

3. Method according to claim 2, characterized in that TOCR is obsessive-compulsive disorder (OCD).

4. A method for treating Tourette Syndrome, characterized by the fact that it comprises administering to an individual in need thereof a therapeutically effective amount of betahistine or a pharmaceutically acceptable prodrug, derivative, metabolite, cocrystal, modification, salt, free acid or base, solvate, hydrate, isotope, tautomer, ester, polymorph or stereoisomer thereof.

5. A method for treating obsessive-compulsive disorder (OCD) in a human being, characterized by comprising the oral administration, to a human being in need of such treatment, of an effective amount of an H1R agonist and / or an H3R antagonist, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof.

6. A method for treating disorders related to glutamate excitotoxicity in a human being, characterized in that it comprises the oral administration, to a human being in need of such treatment, of an effective amount of an H1R agonist and / or an H3R antagonist, or of a pharmaceutically acceptable salt, metabolite or prodrug thereof. Petition 870260106243, dated 10 / 15 / 2026, p. 41 / 106 2 / 6 7. A method for treating autism spectrum disorder in a human being, characterized in that it comprises administering orally, to a human being in need of such treatment, an effective amount of an H1R agonist, or of an H1R antagonist in combination with an H3R antagonist, or of a pharmaceutically acceptable salt, metabolite or prodrug thereof.

8. A method for treating disorders related to glutamate excitotoxicity, characterized by the fact that it comprises administering to an individual in need thereof a therapeutically effective amount of betahistine or a pharmaceutically acceptable prodrug, derivative, metabolite, cocrystal, modification, salt, free acid or base, solvate, hydrate, isotope, tautomer, ester, polymorph or stereoisomer thereof.

9. Method according to claim 8, characterized in that the disorder related to glutamate excitotoxicity is selected from the group consisting of amyotrophic lateral sclerosis (ALS), Parkinson's disease, traumatic brain injury, concussion or post-concussion syndrome, cerebral infarction or stroke, multiple sclerosis, Huntington's disease, schizophrenia, seizure, epilepsy, epileptic syndrome, status epilepticus, refractory focal epilepsy, autoimmune encephalitis, infectious encephalitis, viral encephalitis, acute disseminated encephalomyelitis or mitochondrial encephalitis.

10. A method for treating tic disorders, characterized by the fact that it comprises administering to an individual in need thereof a therapeutically effective amount of betahistine or a pharmaceutically acceptable prodrug, derivative, metabolite, cocrystal, modification, salt, free acid or base, solvate, hydrate, isotope, tautomer, ester, polymorph or stereoisomer thereof.

11. Method according to claim 10, characterized in that the tic disorder is selected from the group consisting of Tourette Syndrome or Tourette Disorder, chronic motor tic disorder, chronic vocal tic disorder, transient tic disorder, and substance-induced tic disorder.

12. Method of treatment of autism spectrum disorder (ASD) in a human being, characterized by the fact that it comprises the oral administration, to a human being in need of such treatment, of an effective amount of betahistine or a pharmaceutically acceptable prodrug, derivative, metabolite, cocrystal, modification, salt, free acid or base, solvate, hydrate, isotope, tautomer, ester, polymorph or stereoisomer thereof.

13. A method according to any one of claims 1 to 12, characterized in that betahistine or a pharmaceutically acceptable prodrug, derivative, metabolite, cocrystal, modification, salt, free acid or base, solvate, hydrate, isotope, tautomer, ester, polymorph or stereoisomer thereof is administered in combination with one or more other therapeutically active compounds.

14. Method according to claim 13, characterized in that the other therapeutically active compound is selected from the group consisting of a monoamine oxidase inhibitor (MAOI), a serotonin / norepinephrine dual reuptake inhibitor (SNRI), an antidepressant, a glutamate modulator, a benzothiazole or benzothiazole derivative, a serotonin reuptake inhibitor (SSRI), a skeletal muscle relaxant, an antipsychotic agent, an antidepressant, an anticholinergic, an anticonvulsant, and a benzodiazepine or benzodiazepine derivative or a combination thereof.

15. A method according to any one of claims 1 to 14, characterized in that said betahistine or a pharmaceutically acceptable prodrug, derivative, metabolite, cocrystal, modification, salt, free acid or base, solvate, hydrate, isotope, tautomer, ester, polymorph or stereoisomer thereof is administered orally, intravenously, sublingually, buccally, transdermally or intranasally.

16. Method according to claim 15, characterized in that said betahistine or a pharmaceutically acceptable prodrug, derivative, metabolite, cocrystal, modification, salt, free acid or base, solvate, hydrate, isotope, tautomer, ester, polymorph or stereoisomer thereof is administered orally.

17. Method according to any one of claims 1 to 16, characterized in that said betahistine or a pharmaceutically acceptable prodrug, derivative, tabolite, cocrystal, modification, salt, free acid or base, solvate, hydrate, isotope, tautomer, ester, polymorph or stereoisomer thereof is administered in combination with a neuromodulation technique selected from the group consisting of transcranial direct current stimulation (tDCS), transcranial magnetic stimulation (TMS), deep brain stimulation (DBS) or a combination thereof.

18. A method according to any one of claims 1 to 17, characterized in that said betahistine or a pharmaceutically acceptable prodrug, derivative, metabolite, cocrystal, modification, salt, free acid or base, solvate, hydrate, isotope, tautomer, ester, polymorph or stereoisomer thereof is selected from the group consisting of betahistine dihydrochloride, betahistine mesylate, a deuterated betahistine and a betahistine prodrug.

19. A method according to any one of claims 1 to 18, characterized in that said betahistine or a pharmaceutically acceptable prodrug, derivative, metabolite, cocrystal, modification, salt, free acid or base, solvate, hydrate, isotope, tautomer, ester, polymorph or stereoisomer thereof is administered once daily, twice daily, three times daily or more than three times daily.

20. A method according to any one of claims 1 to 19, characterized in that said betahistine or a pharmaceutically acceptable prodrug, derivative, metabolite, cocrystal, modification, salt, free acid or base, solvate, hydrate, isotope, tautomer, ester, polymorph or stereoisomer thereof is administered less than once a day.

21. A method according to any one of claims 1 to 20, characterized in that said betahistine or a pharmaceutically acceptable prodrug, derivative, metabolite, cocrystal, modification, salt, free acid or base, solvate, hydrate, isotope, tautomer, ester, polymorph or stereoisomer thereof is administered such that the total weekly dose is from 50 to 2,000 mg.

22. Method according to any one of claims 1 to 21, characterized in that it comprises administering a compound of Formula I: Petition 870260106243, dated 10 / 15 / 2026, page 44 / 106 5 / 6 Formula I wherein, R1-R4 are each independently selected from either hydrogen or deuterium; R5-R7 are each independently selected from either hydrogen or deuterium; R9-R11 are each independently selected from either hydrogen or deuterium; and R12 is selected from hydrogen, deuterium, optionally substituted alkyl, optionally substituted aryl, -C(O)Ri3, -S(O)Ri3, -S(O)2Ri3, -C(O)OR13, -P(O)2ORi3, -N(Ri3)(Ri4), wherein R13 and R14 are independently selected from hydrogen, optionally substituted alkyl or optionally substituted aryl, provided that at least one of R1-R12 is different from hydrogen or deuterium; and pharmaceutically acceptable salts thereof.

23. Method according to any one of claims 5 to 7, 9 or 22, characterized in that said H1R agonist is selected from the group consisting of methylhistaprodifen, dimethylhistaprodifen, 2-thiazolylethylamine, 2-pyridylethylamine, suprahistaprodifen, 2-(2-aminoethyl)pyridine (2-PyEA), a 2-phenylhistamine, such as 2-[3-(trifluoromethyl)phenyl]histamine, 2-(3-chlorophenyl)histamine, N-methyl-2-[3-(trifluoromethyl)phenyl]histamine, histaprodifen (2-[2-(3,3-diphenylpropyl)-1H-imidazol-4-yl]ethanamine), suprahistaprodifen (N-2-[(1H-imidazol-4-yl)ethyl] histaprodifeno-(2-aminoethyl)imidazole (2-lmEA), an H1 agonist synthesized from a new orientation or alteration in the imidazole ring, and said H3R antagonist is selected from the group consisting of A-960656, ABT-239, ABT-288, ABT-652, ABT-834, APD-916, AZD-5213, bavisant (BEN2001, JNJ1074, Petition 870260106243, 10 / 15 / 2026, p. 45 / 106 6 / 6 JNJ31001074), betahistine (AM125, AM201), BP1.3656, CEP-32215, cipralisant, ciproxfan, clobenpropit, DL-76, DL-77, E-100, E-162, enerisanthus, GR175737, GSK1004723, GSK-189254, GSK207040, GSK-239512, GSK-334429, GSK-835726, GT2016, HPP-404, irdabisanto (CEP-26401), JNJ-17216498, JNJ-39220675, JNJ5207852, LC-1405, LGD-3437, LML-134, MK-0249, MK-3134, MK-7288, PF03654746, pitolisanto (BF2649), S013-1593, S-38093, samelisanto (SUVN G3031), SAR-110894, SAR-152954, SCH-497079, SLS-010, ST-1283, tioperamide, ZPL868087, and pharmaceutically acceptable salts, metabolites and prodrugs thereof.